Charles Schwab Investment Management Inc Corvus Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 29,968 shares of CRVS stock, worth $130,061. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,968
Previous 15,668
91.27%
Holding current value
$130,061
Previous $82,000
89.02%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CRVS
# of Institutions
102Shares Held
38.1MCall Options Held
2.75MPut Options Held
1.17M-
Orbimed Advisors LLC San Diego, CA6.94MShares$30.1 Million0.98% of portfolio
-
Samlyn Capital, LLC New York, NY6.67MShares$28.9 Million0.56% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$14.2 Million18.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.03MShares$13.2 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$11.6 Million0.23% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $202M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...